Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiplex RT-PCR-Based Sequencing Assay to Detect Kidney Cancer-Specific Splice Variants in Tumor Tissues and Plasma Cell-Free RNAs.

Molecular diagnosis & therapy·2026
Same author

Clinico-genomic nomograms for estimation of survival risk in metastatic castrate-resistant prostate cancer.

JNCI cancer spectrum·2026
Same author

Rare Gastric Hamartomatous Inverted Polyp in Duodenum Resected by Endoscopy.

Digestive diseases and sciences·2026
Same author

Chemoselective 1,2-Sulfonamidoazidation of Styrene via Single-Atom-Site Cobalt Catalysis.

Journal of the American Chemical Society·2026
Same author

The emerging regulatory roles of non-coding RNA in Ventilator-induced Lung Injury.

Non-coding RNA research·2026
Same author

Severe burns complicated by EDKA, CDI, and NTIS: A case report and literature review.

Medicine·2026

Related Experiment Video

Updated: Nov 29, 2025

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.6K

Prospects for Clinical Development of Stat5 Inhibitor IST5-002: High Transcriptomic Specificity in Prostate Cancer

Cristina Maranto1,2,3, Vindhya Udhane1,2,3, Jing Jia4

  • 1Department of Pathology, Medical College of Wisconsin Cancer Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA.

Cancers
|November 21, 2020
PubMed
Summary

The Stat5 inhibitor IST5-002 effectively targets prostate cancer and related disorders. This study confirms IST5

Keywords:
IST5-002Stat5cell signalingprostate cancersmall-molecule inhibitorstoxicitytranscriptome

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.5K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.1K

Related Experiment Videos

Last Updated: Nov 29, 2025

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.6K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.5K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.1K

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Signal transducer and activator of transcription 5 (Stat5a/b) is a key target for prostate cancer (PC) and hematological disorders.
  • Developing specific Stat5 inhibitors is crucial for novel therapeutic strategies.

Purpose of the Study:

  • To evaluate the transcriptomic specificity and mechanism of action of the Stat5 inhibitor IST5-002 (IST5) in prostate cancer.
  • To assess the in vivo toxicity of IST5 for potential clinical development.

Main Methods:

  • RNA sequencing (RNA-seq) to compare IST5 transcriptomic effects with Stat5 knockdown.
  • In vitro kinase assays and cell-based assays to determine IST5's inhibitory activity and mechanism.
  • Acute, sub-chronic, and chronic toxicity studies in mice.

Main Results:

  • IST5 demonstrated high transcriptomic similarity (Pearson correlation 0.98-0.99) to genetic Stat5 knockdown.
  • IST5 effectively suppressed Stat5 phosphorylation and dimerization in PC cells without broad kinase inhibition.
  • The phosphate group was not essential for IST5's cellular activity.
  • No significant toxic effects or blood profile changes were observed in mice across various toxicity studies.

Conclusions:

  • IST5 is a specific Stat5 inhibitor with a favorable safety profile in preclinical studies.
  • Further optimization of IST5 for oral bioavailability is warranted for clinical development in solid tumors and hematological disorders.